Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Celgene Corporation to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone011-353-1236-2500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$950,000.00
Profitability
Miscellaneous
Employees59
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Prothena (NASDAQ:PRTA) Frequently Asked Questions
What is Prothena's stock symbol?
Prothena trades on the NASDAQ under the ticker symbol "PRTA."
How were Prothena's earnings last quarter?
Prothena Co. PLC (NASDAQ:PRTA) announced its quarterly earnings results on Thursday, February, 14th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by $0.04. The biotechnology company had revenue of $0.19 million for the quarter, compared to analysts' expectations of $0.28 million. Prothena had a negative net margin of 16,297.91% and a negative return on equity of 38.98%. View Prothena's Earnings History.
When is Prothena's next earnings date?
What price target have analysts set for PRTA?
9 brokers have issued twelve-month price targets for Prothena's shares. Their predictions range from $12.00 to $87.00. On average, they anticipate Prothena's stock price to reach $33.9671 in the next twelve months. This suggests a possible upside of 217.4% from the stock's current price. View Analyst Price Targets for Prothena.
What is the consensus analysts' recommendation for Prothena?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Prothena.
What are Wall Street analysts saying about Prothena stock?
Here are some recent quotes from research analysts about Prothena stock:
- 1. According to Zacks Investment Research, "Prothena's license agreement with Roche for prasinezumab is big positive as it not only boosts Prothena’s pipeline development but also provides it with funds in the form of research reimbursement and milestone payments. The company also entered into an agreement with Celgene to develop its pipeline which should boost investor sentiment given the latter’s expertise. However, Prothena suffered a major setback with the discontinuation of development of lead candidate NEOD001. Moreover, due to disappointing data from a phase Ib study, the company will not advance PRX003 into mid-stage development. Consequently, the company has decided to reduce its workforce by 57%. The lack of promising candidates is a concern. Shares have performed worse than the industry in the last six months. Estimates looks stable ahead of the Q4 earnings release. Prothena has a mixed record of earnings surprises in recent quarters." (2/13/2019)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and 12-month PT of $18. With discontinuation of NEOD001 development announced in April (our report here), investors are likely to focus on PRX002/RG7935 development as a treatment for Parkinson’s disease (PD). The company has guided to expectation for data from the Phase 2 PASADENA trial in 2020. Release of pharmacodynamic data from lower-dose cohorts of ATTR amyloidosis treatment PRX004 are anticipated in 2019." (8/8/2018)
Has Prothena been receiving favorable news coverage?
Media coverage about PRTA stock has trended neutral recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Prothena earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future.
Who are some of Prothena's key competitors?
Some companies that are related to Prothena include Enanta Pharmaceuticals (ENTA), Madrigal Pharmaceuticals (MDGL), Allakos (ALLK), Endo International (ENDP), Zogenix (ZGNX), Mallinckrodt (MNK), Pacira Biosciences (PCRX), Opko Health (OPK), Prestige Consumer Healthcare (PBH), Corcept Therapeutics (CORT), Phibro Animal Health (PAHC), Tricida (TCDA), Innoviva (INVA), Inflarx (IFRX) and Myovant Sciences (MYOV).
What other stocks do shareholders of Prothena own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Canopy Growth (CGC), Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), Celgene (CELG), Synergy Pharmaceuticals (SGYP), Perrigo (PRGO) and ACADIA Pharmaceuticals (Acad).
Who are Prothena's key executives?
Prothena's management team includes the folowing people:
- Mr. Gene G. Kinney, Pres, CEO & Director (Age 50)
- Mr. Tran B. Nguyen, CFO & COO (Age 45)
- Mr. Arthur W. Homan, Chief Legal Officer & Company Sec. (Age 60)
- Ms. Karin L. Walker, Chief Accounting Officer & Controller (Age 56)
- Dr. Wagner M. Zago, Chief Scientific Officer (Age 46)
How do I buy shares of Prothena?
Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Prothena's stock price today?
One share of PRTA stock can currently be purchased for approximately $10.70.
How big of a company is Prothena?
Prothena has a market capitalization of $426.50 million and generates $950,000.00 in revenue each year. The biotechnology company earns $-155,650,000.00 in net income (profit) each year or ($3.61) on an earnings per share basis. Prothena employs 59 workers across the globe.
What is Prothena's official website?
How can I contact Prothena?
Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN L2, D02 T804. The biotechnology company can be reached via phone at 011-353-1236-2500 or via email at [email protected]
MarketBeat Community Rating for Prothena (NASDAQ PRTA)
MarketBeat's community ratings are surveys of what our community members think about Prothena and other stocks. Vote "Outperform" if you believe PRTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
